ORIC Annual Report FY2026
ORIC Annual Report FY2026
Quality Scores
Latest Quarterly Earnings Summary
No quarterly summary available yet.
AI Summary
ORIC Pharmaceuticals is a clinical-stage precision oncology company focused on overcoming resistance mechanisms in cancer. The firm relies on a diverse pipeline, specifically targeting androgen receptor (AR) and glucocorticoid receptor (GR) pathways. Since its 2020 IPO, ORIC has maintained a robust cash position but remains a pre-revenue venture typical of the biotech sector. Its investment thesis hinges entirely on clinical trial outcomes rather than current financial performance. The company’s strategic partnerships, such as those with Pfizer, provide external validation of its research…
Key Changes in FY2026
ORIC has evolved from a discovery-stage startup focused on 'Overcoming Resistance in Cancer' to a multi-asset clinical-stage biopharmaceutical firm. Since its IPO in 2020, the company has transitioned from preclinical models to active Phase 1/2 trials for its lead candidates ORIC-114, ORIC-944, and ORIC-533. The strategy has expanded from general oncology to precision medicine targeting specific mutations in prostate cancer and NSCLC. Strategic partnerships, most notably with Bayer and Pfizer (through the Breakthrough Growth Initiative), have validated the platform's potential. The business is currently moving up the value chain by transitioning into mid-to-late stage clinical development.
Management Commentary
The management team is composed of seasoned biotech executives with significant experience from Genentech and other major pharma players. CEO Jacob Chacko provides clear strategic direction, focusing on high-unmet-need oncology markets. Communication is technically proficient and transparent regarding trial timelines and data readouts. While scientific expertise is high, management’s primary challenge lies in navigating the FDA's regulatory hurdles. Alignment with shareholders is maintained through equity-based compensation, though dilution remains a necessary byproduct of growth.
Financial Highlights
ORIC generates no commercial revenue, with its income statement characterized by consistent research and development (R&D) and general and administrative (G&A) expenses. Net losses have widened as programs move from discovery into Phase 1/2 clinical trials. Operating expenses are primarily driven by the development of its lead candidates, ORIC-944 and ORIC-114. The company maintains a strong balance sheet with approximately $200-$300 million in cash and equivalents, providing a multi-year runway. However, the lack of recurring revenue makes traditional margin analysis irrelevant at this stage.
Major Opportunities
- Robust cash position relative to current market cap
- Strategic partnership with Pfizer (ORIC-944)
- Focus on overcoming resistance in cancer (high unmet need)
Major Risks
- No steady revenue stream currently
- Consistently high annual cash burn (> $90M)
- Significant reliance on future equity raises
About This Annual Report
The ORIC FY2026 Annual Report is the company's flagship annual disclosure, filed with SEC EDGAR. It covers the full-year business review, management discussion & analysis (MD&A), audited financial statements, director's report, corporate governance report, auditor's report, risk factors, capital allocation, subsidiaries, related-party transactions and ESG initiatives. This page consolidates the official PDF and an AI-generated summary so investors can quickly grasp what changed vs. prior years — sales growth, margin trend, cash flow quality, capex, dividends and management outlook — without having to read the entire filing.
Why Use AI?
- Summarises hundreds of pages into a focused executive briefing
- Identifies year-on-year key changes automatically
- Extracts management commentary and tone
- Highlights top risks and opportunities
- Compares business evolution vs. earlier years
- Answers your questions in plain English via Ask AI
Frequently Asked Questions
Related Research
AI Top Insights — Premium
Unlock deeper AI Top Insights, advanced comparisons, downloadable reports and premium features.